Axia Pharmaceutical Recalls Lysine Hydrochloride Injection Due to Sterility Concerns
Axia Pharmaceutical is recalling specific lots of Lysine Hydrochloride Injection because the company cannot ensure the product is sterile.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in an injectable medication, which poses a significant risk of serious injury or infection.
Plain-English summary
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical is recalling Lysine Hydrochloride Injection, 100mg/mL, 30 mL multi-dose vials. The recall is being conducted because the company lacks assurance of the sterility of the product.
The affected product is identified by NDC 71283-0342-3, Lot # 10222019+53144, and an expiration date of 1/27/2020. The product was distributed nationwide in the U.S.A., as well as in Puerto Rico, Barbados, and the Dominican Republic.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or the manufacturer for further instructions.
The recalled product
- Product
- Lysine Hydrochloride Injection, LYSINE HCL 100MG/ML INJECTABLE, For IV, IM Use, 30 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0342-3
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 10222019+53144
- Exp 1/27/2020
Distribution
Part of a larger recall action
This product is one of 63 recalled by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 63 products in this recall →Related recalls
Same manufacturer · Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
See all →- Severe
- SevereAxia Pharmaceutical Recalls Selenium Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- Severe
- SevereAxia Pharmaceutical Recalls Hydroxyprogesterone Caproate Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- SevereAxia Pharmaceutical Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
Same hazard · sterility
See all →- SevereAurolab Trust Recalls FOCUS PI Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-10-07
- SevereSterling Recalls Carboxymethylcellulose Sodium Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereSterling Pharmaceutical Recalls Lubricating Tears Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereWalgreens Lubricant Eye Drops Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2026-09-30
- SevereSodium Chloride Ophthalmic Solution Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
Similar recalls
- SeverePromise Pharmacy Recalls Lysine HCl Injection Due to Sterility Concerns
FDA (Drugs) · 2019-02-20
- Severe
- SevereAxium Healthcare Recalls Triamcinolone Hexacetonide Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-05-01
- SevereGreen Valley Drugs Recalls L-Lysine Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-22
- Severe
- SevereAxium Healthcare Recalls Comprehensive Injection #4 Due to Sterility Concerns
FDA (Drugs) · 2013-05-01